The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Ĭao JX, Wang H, Gao WJ, You J, Wu LH, Wang ZX. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Īnagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment? Front Immunol 2020 11:603237. Sadeqi Nezhad M, Seifalian A, Bagheri N, Yaghoubi S, Karimi MH, Adbollahpour-Alitappeh M. Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy. Yang C, Lei W, Xie H, Wu G, Wei J, Liang A, Qian W. CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety. Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds. Hamilton JAG, Lee MY, Hunter R, Ank RS, Story JY, Talekar G, Sisroe T, Ballak DB, Fedanov A, Porter CC, Eisenmesser EZ, Dinarello CA, Raikar SS, DeGregori J, Henry CJ. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success. Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric Antigen Receptor T Cell Therapy. Wudhikarn K, Flynn JR, Rivière I, Gonen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, Park J. The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy. ĭholaria B, Savani BN, Huang XJ, Nagler A, Perales MA, Mohty M. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. Qin H, Yang L, Chukinas JA, Shah N, Tarun S, Pouzolles M, Chien CD, Niswander LM, Welch AR, Taylor N, Tasian SK, Fry TJ. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo. Guo C, Dong E, Lai Q, Zhou S, Zhang G, Wu M, Yue X, Tao Y, Peng Y, Ali J, Lu Y, Fu Y, Lai W, Zhang Z, Ma F, Yao Y, Gou L, Yang H, Yang J. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies. Zhang ZZ, Wang T, Wang XF, Zhang YQ, Song SX, Ma CQ.
Qcart trial update#
Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects. Qian S, Villarejo-campos P, Guijo I, Hernández-villafranca S, García-olmo D, González-soares S, Guadalajara H, Jiménez-galanes S, Qian C. Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies. Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML. Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse. Liu L, Ma C, Zhang Z, Witkowski MT, Aifantis I, Ghassemi S, Chen W. Li S, Zhang J, Wang M, Fu G, Li Y, Pei L, Xiong Z, Qin D, Zhang R, Tian X, Wei Z, Chen R, Chen X, Wan J, Chen J, Wei X, Xu Y, Zhang P, Wang P, Peng X, Yang S, Shen J, Yang Z, Chen J, Qian C. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
0 kommentar(er)
